Blood Clots, A Very Common Symptom In Persons With Severe COVID-19

THERE is a high probability of recording high blood clots cases in persons who are admitted in the Intensive Care Unit (ICU) and those with severe COVID-19 symptoms than in other groups, a top immunologist has said. By Michael Gwarisa Speaking during an informal meeting with Journalists recently, Dr Tinashe Gede said in as much as there has been concern over people developing blood clots from vaccines elsewhere in the world, the incidence of thrombosis or blood clots, COVID-19 had proved to be the most highly pro-thrombotic illness to have…

Read More

Zimbabwe Should Rethink Vaccine Deployment Strategy

ZIMBABWE has been urged to re-look its national vaccination distribution strategy in order to increase uptake and move close towards vaccinating at least 60 percent of the population. By Michael Gwarisa The country commenced vaccinating its citizens in March 2021 following a delivery of the Sinopharm doses from the Republic of China. Even though at first, there was vaccine hesitancy more people are now coming forward willingly to get vaccinated. However, there been reports of shortages of vaccines dosses across the country of late. Immunologist and Medical Expert, Dr Tinashe…

Read More

WHO Zimbabwe Expert Clarifies On Sinopharm Vaccine, Says Sinopharm And More Other Vaccines Awaiting WHO Emergency Use Approval

There is nothing unusual about Sinopharm being administered before getting the WHO SAGE approval Only Four Vaccines have received the WHO EUL approval SAGE likely to make recommendations to Sinopharm end of March or beginning of April THE Sinopharm, Sinovac, Suptnik and at least 30 more other vaccines have submitted their dossiers to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) for them to be listed for emergency use amidst indications that to date, only four vaccines namely the Pfizer Biotech, Astrazeneca, Mordena and Johnson & Johnson…

Read More

Oxford Coronavirus Vaccine Trial Paused After Participant Develops Rare Illness Says AstraZeneca

LATE-stage trials for a leading coronavirus vaccine have been suspended after a study participant suffered a “potentially unexplained illness”. AstraZeneca has put on hold phase three trials of a vaccine being developed in collaboration with the University of Oxford. The Australian Government last month signed an agreement with the UK-based company to secure the potential COVID-19 vaccine, if its trials prove successful. In a statement, AstraZeneca said it “voluntarily paused” the phase 3 clinical trial — which kicked off in July — to allow a review of the “single event”…

Read More